Revance Office

A merging of innovation for over 25 years

Our Mission

We believe that science-powered innovation creates possibilities. As a privately held, fully-integrated global company, Revance is passionately driven by that philosophy in everything we do. Dedicated to offering a diverse portfolio in aesthetics, skincare, and therapeutics, our science-backed products care for individuals across the generations. By driving innovation beyond convention, we continue to research and develop differentiated products for health, beauty, and wellness.

Our Vision

We devote our passion, energy, and talent to being an innovative leader in the industry with a profound dedication to science.

Revance Office Revance Office Revance Office

Our journey spans over two decades

From our exciting start in 1999, Revance has embarked on a robust journey of research and development, pivotal clinical trials, groundbreaking product launches, and portfolio-building acquisitions. All pointing toward an inspiring future beyond today.

1999

Essentia Biosystems founded by Dan Browne, Michael Dake, MD and Jacob Waugh, MD. Later renamed Revance Therapeutics, Inc.

Explored the potential use of peptide-assisted delivery of macromolecules botulinum toxins that leads to development of DaxibotulinumtoxinA.

2000

Crown Laboratories, Inc is founded.

2001

Crown launches Blue Lizard® sunscreen, its flagship OTC sunscreen.

2008

Revance moved into Newark, CA headquarters in Biotech Bay.

2014

Initiated clinical development for DaxibotulinumtoxinA for Injection in glabellar lines.

Initiated clinical development for DaxibotulinumtoxinA for Injection in cervical dystonia and plantar fasciitis.

2018

Crown acquires Bellus Medical, and GSK assets—launches Beauty and Aesthetics portfolios; OTC becomes Therapeutic Skincare Division.

2019

Crown opens corporate headquarters in Johnson City, TN.

Crown acquires Xycrobe Therapeutics, an innovator in skin microbiome technology.

Revance obtained exclusive rights to the RHA® Collection of dermal fillers in the US.

2020

Revance launched the Teoxane RHA® Collection (RHA® 2, RHA® 3, and RHA® 4) of dermal fillers in the US.

2021

Revance HQ moved to Nashville, TN.

Crown acquires StriVectin.

2022

Revance receives FDA approval for DAXXIFY® for the treatment of glabellar lines—the first true innovation in neuromodulator product formulation in over 20 years.¹

2023

DAXXIFY® approved for the treatment of cervical dystonia in adults.

2024

Crown acquires Healeon assets.

2025

Crown acquires Revance and both its aesthetics portfolio and its therapeutic offering; company rebrands as REVANCE with HQ in Nashville, TN.

Our products span across the globe

Revance has a comprehensive global presence where our industry-leading, science-powered products are offered in many countries.

Not all products are available in all regions.
Revance products world map
A laptop on a table

Executive Committee

Our dynamic group of leaders represent more than a century of experience in skin science.

Meet our leadership team
Two business people shaking hands

Partnership

To strengthen our purpose and reinforce our product pipeline, we strategically collaborate with unique partners.

Learn about our collaborations

References

  1. FDA Approves BOTOX® Cosmetic (OnabotulinumtoxinA) for the Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines Associated with Frontalis Muscle Activity in Adults. PR Newswire website. Published October 3, 2017. Accessed October 10, 2025.

INDICATION

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION


Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency units of DAXXIFY® are not interchangeable with preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:
Glabellar lines (≥1%): headache (6%), eyelid ptosis (2%) and facial paresis (1%).
Cervical dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (5%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

DAXI-004726

Instagram LinkedIn

©2025 REVANCE. RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The Teoxane RHA® Collection is exclusively distributed by REVANCE. All other trademarks are the property of their respective owners. CORP-00147

Submit a Privacy RequestCalifornia Compliance DeclarationPrivacy PolicyTerms of Use
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.